call 1800 257 600 email [email protected]

Fanconi Anaemia

Fanconi anaemia is a rare genetic disorder that is characterised by various physical abnormalities, bone marrow failure and a predisposition to malignancy (cancer). It is classified as an inherited bone marrow failure syndrome (IBMFS), which is when the bone marrow is unable to produce enough healthy blood cells.

Blood is the bodily fluid of the circulatory system that provides nutrients and oxygen to our tissues, and helps to remove waste from our bodies. There are three primary types of blood cells produced in the inner, spongy portion of the bone (bone marrow) from stem cells (immature blood cells that develop into either red blood cells (RBCs), white blood cells (WBCs), or platelets). RBCs, or erythrocytes, are responsible for providing oxygen to the tissues in our body, as well as transporting carbon dioxide to the lungs to be exhaled. WBCs are responsible for fighting infection and disease in the body. Platelets are blood cells that play a major role in blood clotting (or coagulation), which is an important process that helps reduce blood loss after injury.

Familial cancer syndromes, also known as hereditary cancer syndromes, are rare conditions that cause an increased risk of cancer as the result of inherited genetic mutations in certain cancer-related genes. They can affect both adults and children, however they generally develop in people at a younger age than normal. While familial cancer syndromes are not classified as cancer, they are equally as severe and can be life-threatening as they are associated with the development of various tumours throughout the body. Having a familial cancer syndrome does not guarantee the development of cancer, however the risk of developing cancer is higher than those who do not have a familial cancer syndrome.

Fanconi anaemia occurs when the bone marrow is damaged or not able to work properly, which reduces the capacity of the bone marrow to produce healthy RBCs, WBCs, and platelets. It is caused by a genetic mutation in one of at least 15 different genes.

Fanconi anaemia is slightly more common in males, and tends to be diagnosed before the age of 10. However, anyone can develop this disease.

Fanconi anaemia is most commonly associated with the development of haematological cancers, most notably acute myeloid leukaemia and myelodysplastic syndromes (MDS). However, it has also been linked to other types of tumours. Some examples include:

Treatment

When cancers are detected, they are staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading help your doctors determine the best treatment for you. However, each patient with Fanconi anaemia will present with a unique disease behaviour, with varying tumour locations and symptoms. As such, there is no one treatment method that will work for everyone, and there is no standard staging system for this disease. Instead of staging and grading, your doctor will recommend a treatment plan based on the following factors:

  • Type of tumours present.
  • Whether the tumours are malignant (cancerous) or benign (non-cancerous).
  • Tumour location.
  • Whether or not malignant tumours have metastasised.
  • Your age.
  • General health.
  • Your treatment preferences.

Your doctor may also recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment options for tumours associated with Fanconi anaemia may include:

  • Surgery to remove as much of the tumour(s) as possible – these will vary based on tumour type and location.
  • Chemotherapy (limited).
  • Radiation therapy (limited).
  • Stem cell transplant.
  • Hormone therapy.
  • Targeted therapy.
  • Clinical trials.
  • Palliative care.

Treatment for Fanconi Anaemia and Fertility

Treatment for some of the cancers associated with Fanconi anaemia may make it difficult to become pregnant. If fertility is important to you, discuss your options with your doctor prior to the commencement of treatment.

Cancer Screening

Once a diagnosis of Fanconi anaemia has been confirmed, implementing a targeted screening plan becomes essential due to the increased risk of developing certain cancers.  The content of this plan will vary from person to person based on the genetic mutation involved, your family’s history of cancer and the types of cancers that may be present. It will also outline the routine tests you should have and how regularly you should have them.

Screening options for may evolve as new technologies are developed and our understanding of the condition grows. It is essential to discuss your individual circumstances with your healthcare team to determine the most appropriate screening plan for you.

Risk factors

In most cases, Fanconi anaemia is caused by a genetic mutation in FANCA (Fanconi anaemia, complementation group A), which is a protein coding gene that is involved in DNA repair. However, other genes can potentially also cause the disease, such as:

  • FANCB (Fanconi anaemia complementation group B, involved in DNA repair).
  • FANCC (Fanconi anaemia complementation group C, involved in DNA repair).
  • FANCD (Fanconi anaemia complementation group D, involved in DNA repair).
  • FANCE (Fanconi anaemia complementation group E, involved in DNA repair).
  • FANCF (Fanconi anaemia complementation group F, involved in DNA repair).
  • FANCG (Fanconi anaemia complementation group G, involved in DNA repair).
  • FANCI (Fanconi anaemia complementation group I, involved in DNA repair).
  • BRAC1 (breast cancer gene 1, tumour suppressor gene).
  • BRCA2 (breast cancer gene 2, tumour suppressor gene).
  • BRIP1 (BRCA1 interacting protein C-terminal helicase 1, tumour suppressor gene).
  • ERCC4 (excision repair cross-complementation group 1, DNA repair gene).
  • FANCL (Fanconi anaemia complementation group L, involved in DNA repair).
  • FANCM (Fanconi anaemia complementation group M, involved in DNA repair).
  • PALB2 (partner and localiser of BRCA2, tumour suppressor gene).
  • RAD51C (RAD51 paralog C, tumour suppressor gene).
  • FANCP (Fanconi anaemia complementation group P, involved in DNA repair).
  • UBE2T (ubiquitin-conjugating enzyme 2 T, involved in DNA repair).
  • XRCC2 (x-ray repair cross complementing gene 2, involved in DNA repair).
  • FANCV (Fanconi anaemia complementation group V, involved in DNA repair).

In most cases, Fanconi anaemia is inherited as an autosomal recessive disorder, which means that you have to inherit one gene with the mutation from both parents in order to develop the condition. If both of parents carry the gene, there is a one in four chance of a child having the condition. However, there are two exceptions:

  • FANCB gene (X-linked recessive).
  • RAD51 gene (autosomal dominant).

People with the FANCB genetic mutation have an X-linked recessive disorder, which means that the mutation is found on the X chromosome. This type of inheritance tends to affect males more than females, as they only have one X chromosome. Comparatively, females carrying the mutation in one X chromosome tend to be unaffected, as they have two X chromosomes.

People with the RAD51 genetic mutation have an autosomal dominant disorder, which means that you have a 50% chance of developing the condition if one of your parents carries the mutation.

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

The symptoms of Fanconi anaemia often vary by the type(s) of tumours present. General symptoms of Fanconi anaemia may include:

  • Short stature.
  • Limb abnormalities, potentially including:
    • Extra, misshaped or missing fingers and/or thumbs.
    • Incompletely developed/missing radial bone in the forearm.
  • Genital abnormalities in males, potentially including:
    • Underdeveloped genitalia.
    • Undescended testicles.
    • Hypospadias (a condition where the urethral opening isn’t at the tip of the penis).
    • Atresia of the uterus, vagina and/or ovaries (one or both).
  • Genital abnormalities in females, potentially including:
    • Underdeveloped genitalia.
    • Irregularly shaped uterus.
    • Atresia of the uterus, vagina and/or ovaries (one or both).
  • Skeletal abnormalities of the hips, spine and/or ribs.
  • Structural issues with the kidneys.
  • Abnormal skin pigmentation.
  • Anaemia, which carries its own set of symptoms:
    • Fatigue.
    • Dizziness.
    • Paleness.
    • Dyspnea.
  • Abnormally small head.
  • Small, crossed or widely spaced eyes.
  • Low birth weight.
  • Difficulties with vision and/or hearing.
  • Gastrointestinal difficulties.

Symptoms related to specific tumours can be found on our knowledgebase.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have tumours associated with Fanconi anaemia, they may order some of the following tests to confirm the diagnosis and refer you to a specialist for treatment. The tests required for diagnosis will often vary based on the symptoms present, and where the tumour(s) are suspected to be located.

  • Physical examination.
  • Genetic testing.
  • Pelvic examination.
  • Digital rectal examination (DRE).
  • Blood tests.
  • Imaging tests, potentially including:
    • Ultrasound.
    • MRI (magnetic resonance imaging).
  • Lumbar puncture.
  • Bone marrow aspiration.
  • Exploratory procedures, such as an endoscopy.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.